Ahn WS, Yoo J, Huh SW, Kim CK, Lee JM, Namkoong SE, Bae SM, Lee IP. Protectiveeffects of green tea extracts (polyphenon E and EGCG) on human cervical lesions. Eur J Cancer Prev. 2003 Oct;12(5):383-90. PubMed PMID: 14512803.

Buckley DI, McPherson RS, North CQ, Becker TM. Dietary micronutrientsand cervical dysplasia in southwestern American Indian women. Nutr Cancer 1992;17:179–85

Butterworth CE, Hatch KD, Gore H, Mueller H, Krumdieck CL.Improvement in cervical dysplasia associated with folic acid therapy in users of oral contraceptives. Am J Clin Nutr 1982;35:73–82

Castellsague X, Diaz M, de Sanjose S, Munoz N et al. Herrero R, Franceschi S, et al. Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention. J Natl Cancer Inst 2006;98:303-15.

Combs GF Jr, Gray WP. Chemopreventive agents: selenium. PharmacolTher 1998;79:179–92

Crosbie EJ, Einstein MH, Franceschi S, Kitchener HC. Human papillomavirus and cervical cancer. Lancet. 2013 Sep 7;382(9895):889-99

Cutts FT, Franceschi S, Goldie S, Castellsague X, de Sanjose S,et al. Human papillomavirus and HPV vaccines: a review. Bull World Health Organ. 2007 Sep;85(9):719-26

Dyson N, Howley PM, Munger K, Harlow E. The human papillomavirus-16 E7oncoprotein is able to bind to the retinoblastoma gene product. Science. 1989;243:934-7

El-Bayoumy K. The protective role of selenium on genetic damageand on cancer. Mutat Res 2001;475:123–39.

Garland SM, Hernandez-Avila M, Wheeler CM, Perez G,Harper DM, Leodolter S, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007;356:1928-43.

Ghosh C, Baker JA, Moysich KB, Rivera R, Brasure JR, McCann SE.Dietary intakes of selected nutrients and food groups and risk of cervical cancer. Nutr Cancer 2008;60:331–41

Giannini SL, Hanon E, Moris P, Van Mechelen M, Morel S,Dessy F, et al. Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only. Vaccine 2006;24:5937-49

Giuliano AR. The role of nutrients in the prevention of cervical dysplasiaand cancer. Nutrition 2000;16:570–3.

Harper DM, Franco EL, Wheeler CM, Moscicki AB, Romanowski B, Roteli-Martins CM, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccineagainst human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 2006;367:1247-55

IARC Working Group on the Evaluation of Cancer-preventiveAgents. IARC handbooks of cancer prevention. Vitamin A. Vol. 3. Lyon, France: International Agency for Research on Cancer, 1998.

Jacobs MV, Walboomers JM, Snijders PJ, Voorhorst FJ et al. Distribution of 37 mucosotropic HPV types in women with cytologically normal cervical smears: the age-related patterns for high-risk and low-risk types. Int J Cancer 2000;87:221-7.

Joura EA, Leodolter S, Hernandez-Avila M, Wheeler CM,Perez G, Koutsky LA, et al. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials. Lancet 2007;369:1693-702

Long HJ 3rd, Laack NN, Gostout BS. Prevention, diagnosis, and treatment ofcervical cancer. Mayo Clin Proc. 2007 Dec;82(12):1566-74. Review. PubMed PMID: 18053467.

Melkert PW, Hopman E, Van den Brule AJ, Risse EK, Van Diest PJ, Bleker OP, et al. Prevalence of HPV in cytomorphologically normal cervical smears, as determined by the polymerase chain reaction, is age-dependent. Int J Cancer 1993;53:919-23

Munoz N, Castellsague X, de Gonzalez AB, Gissmann L. Chapter 1: HPV in the etiology of human cancer. Vaccine 2006;24S3:S1-10

Myung SK, Ju W, Kim SC, Kim H; Korean Meta-analysis (KORMA) Study Group.Vitamin or antioxidant intake (or serum level) and risk of cervical neoplasm: a meta-analysis. BJOG. 2011 Oct;118(11):1285-91

Olsson SE, Villa LL, Costa RL, Petta CA, Andrade RP,Malm C, et al. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine. Vaccine 2007;25:4931-9

Parkin DM, Bray F. Chapter 2: The burden of HPV-related cancers. Vaccine 2006;24 Suppl 3:S11-25.

Ramakrishnan S, Partricia S, Mathan G. Overview of high-risk HPV's 16 and 18 infected cervical cancer: Pathogenesis to prevention. Biomed Pharmacother. 2015 Mar;70:103-110

Roden R, Wu TC. How will HPV vaccines affect cervicalcancer? Nat Rev Cancer 2006;6:753-63

Scheffner M, Werness BA, Huibregtse JM, Levine AJ, Howley PM. The E6 oncoproteinencoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell. 1990;63:1129-36.

Schiffman MH, Bauer HM, Hoover RN, Glass AG, Cadell DM, Rush BB, Scott DR, Sherman ME, Kurman RJ, Wacholder S, et al. Epidemiologic evidence showing that human papillomavirus infection causes most cervical intraepithelial neoplasia. J Natl Cancer Inst. 1993 Jun 16;85(12):958-64. PubMed PMID: 8388478

Siegel EM, Salemi JL, Villa LL, Ferenczy A, Franco EL, Giuliano AR. Dietaryconsumption of antioxidant nutrients and risk of incident cervical intraepithelial neoplasia. Gynecol Oncol. 2010 Sep;118(3):289-94

Siegel EM, Salemi JL, Villa LL, Ferenczy A, Franco EL, Giuliano AR. Dietaryconsumption of antioxidant nutrients and risk of incident cervical intraepithelial neoplasia. Gynecol Oncol. 2010 Sep;118(3):289-94

Smith JF, Brownlow M, Brown M, Kowalski R, Esser MT, Ruiz Wet al. Antibodies from women immunized with Gardasil ((R)) crossneutralize HPV 45 pseudovirions. Hum Vaccin 2007;3;109-15

Smith JF, Brownlow MK, Brown MJ, Esser MT, Ruiz W,Brown DR. Gardasil antibodies cross-neutralize pseudovirion infection of vaccine-related HPV types. 23rd International Papillomavirus Conference and Clinical Workshop. Prague. 2006

Tay SK. Genital oncogenic human papillomavirus infection:a short review on the mode of transmission. Ann Acad Med Singapore 1995;24:598-601

Thomison J 3rd, Thomas LK, Shroyer KR. Human papillomavirus: molecular and cytologic/histologic aspects related to cervical intraepithelial neoplasia and carcinoma. Hum Pathol. 2008 Feb;39(2):154-66

Tomljenovic L, Shaw CA. Human papillomavirus (HPV) vaccine policy andevidence-based medicine: are they at odds? Ann Med. 2013 Mar;45(2):182-93

Tomljenovic L, Wilyman J, Vanamee E, Bark T, Shaw CA. HPV vaccines and cancer prevention, science versus activism. Infect Agent Cancer. 2013 Feb 1;8(1):6

Vaccarella S, Herrero R, Snijders PJ, Dai M, Thomas JO, Hieu NT, Ferreccio Cet al. Smoking and human papillomavirus infection: pooled analysis of the International Agency for Research on Cancer HPV Prevalence Surveys. Int J Epidemiol. 2008 Jun;37(3):536-46

Verhoeven V, Renard N, Makar A et al. Probiotics enhance the clearance of human papillomavirus-related cervical lesions: a prospective controlled pilot study. Eur J Cancer Prev. 2013 Jan;22(1):46-51

Weinstein SJ, Ziegler RG, Frongillo EA Jr, Colman N, Sauberlich HEet al. Low serum and red blood cell folate are moderately, but nonsignificantly associated with increased risk of invasive cervical cancer in U.S. women. J Nutr 2001;131:2040–8